Vicinitas Therapeutics specializes in developing protein stabilization platforms that can be used in therapeutics for cancer and genetic disorders, according to a July 28 news release from the biotechnology company.
Vicinitas Therapeutics founder Daniel K. Nomura, PhD stated he was excited about the potential for developing “novel therapies against therapeutic targets that were previously deemed undruggable and will respond to protein stabilization.”
A16z and Deerfield Management led the fundraising round with participation from GV.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.